Author: Jane Edwards|| Date Published: February 7, 2018
The Food and Drug Administration has awarded Booz Allen Hamilton (NYSE: BAH) and Octo Consulting Group spots on a potential seven-year, $300 million blanket purchase agreement to update data collection and analysis systems in support of FDA™s patient safety and drug development efforts, the Washington Business Journal reported Tuesday.
Octo said Tuesday it will work with FDA™s center for drug evaluation and research to modernize and maintain an informatics platform that works to streamline the regulatory process and support oversight of biological and pharmacological drugs.
The company noted its partnership with CDER will also help FDA comply with the 21st Century Cure Act.
The Reston, Virginia-based government technology services contractor will also assist FDA to facilitate drug evaluation processes that include human drug data management, review and submission; training support; and full application lifecycle development, maintenance and operations services.
Octo has provided data analytics and management support services at several agencies such as the National Institutes of Health, U.S. Army and the U.S. Patent Trademark Office.
The Naval Information Warfare Center Pacific is soliciting proposals for the development and fielding of intelligence, surveillance and reconnaissance systems…
The Department of War is accelerating its push into unmanned systems, moving beyond experimentation toward large-scale production, streamlined acquisition and…
BAE Systems has received a $117.7 million contract modification from the U.S. Navy to support depot-level modernization, maintenance and repair of USS…
Advanced wireless infrastructure is becoming as strategically important as artificial intelligence in modern defense operations 5G standalone enables network slicing,…
The Food and Drug Administration has awarded Booz Allen Hamilton (NYSE: BAH) and Octo Consulting Group spots on a potential seven-year, $300 million blanket purchase agreement to update data collection and analysis systems in support of FDA™s patient safety and drug development efforts, the Washington Business Journal reported Tuesday.
